SEINE BIO · SCIENCE LIBRARY
CJC-1295 + Ipamorelin / Foundation stack
This pairing is discussed as a GH-signaling combination; Foundation is one informal nickname.
Nonstandard stack nameA closer look at the research, the uncertainties and the questions worth asking.
THE FULL READING GUIDE · UPDATED OCTOBER 7, 2026
Inside the science of CJC-1295 + Ipamorelin / Foundation stack.
Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.
Compounding is appropriate only when lawful for the specific substance and patient; some substances may be unavailable. Finished FDA-approved medicines may also be dispensed by licensed non-compounding pharmacies.
Overview
CJC-1295 plus ipamorelin is an informal growth-hormone-secretagogue pairing sometimes called a Foundation stack. It is not a standardized approved medicine. CJC-1295 with DAC and compounds marketed as no-DAC CJC are not interchangeable. Identifying the exact molecule and formulation is essential before interpreting any trial or combination claim.
Community Use
PeptideDosages has a no-DAC CJC/ipamorelin blend protocol and Peptidepedia discusses the pairing. Both are community sources, not validated prescribing standards. A protocol’s ratio or schedule should not be mistaken for evidence that the exact blend was studied in people. Community blend protocol; Community comparison.
Doses, Durations & Cycles
Informal biohacking protocols and published regimens. Attributed website reports for education, not medical recommendations. Multiple publications document circulation; they do not establish a safe dose or validate a cycle.
| Route / formulation | Dose / reported phases | Frequency | Duration / break | Notes and source |
|---|---|---|---|---|
| Both subcutaneous | Days 1–14: 100 mcg each per injection. Active phase: 200–300 mcg each per injection. | Days 1–14: twice daily. Active phase: two to three times daily. | Typical course 8–12 weeks; phase table labels active dosing weeks 2–12. Break: 4 weeks; repeat courses two to three times per year is separately claimed. | Published informal biohacking claim Active Biolabs Explicit paired no-DAC protocol. Source phases overlap at week 2. DAC alternatives are excluded from this claim. |
| Both subcutaneous | Standard: CJC-1295 100–300 mcg + ipamorelin 200–300 mcg per administration. | Bedtime, five days on/two off; daily is separately described for courses under eight weeks. | 1–3 months; separately mentions three-month body-composition courses. Break: 2–3 months; alternative three-month course with one month off. | Published informal biohacking claim VialBase The source also publishes a distinct higher-intensity example: 300 mcg each twice daily for eight weeks, then eight weeks off. Neither example establishes a safe maximum. |
Important context: Two distinct publishers give explicit paired no-DAC doses and schedules. Their dose progression, daily frequency and breaks disagree; retain attribution. Foundation is an informal alias rather than a standardized drug product. Published schedules are not clinical recommendations, averages or safety limits.
Sources checked October 7, 2026. Educational listing does not establish prescribing approval or availability through Seine Bio.
There is no validated human wellness dose or cycle for this combination. Human CJC studies concern a long-acting DAC product, while cited ipamorelin clinical exposure includes intravenous postoperative research. Those separate exposures cannot be combined into a validated subcutaneous fitness regimen.
Research Findings
FDA assessments summarize individual CJC-1295 and ipamorelin evidence, including the importance of molecular identity and clinical route. They do not establish an effective human combination program. A growth-hormone-marker response in a single-agent study is not proof of recovery or anti-aging benefit from the stack. FDA CJC-1295 review; FDA ipamorelin review.
U.S. Approval & Access
No FDA-approved CJC/ipamorelin combination is established here. A compounding advisory discussion is not approval, and legal supply must be evaluated for each ingredient and applicable pathway. A program name or clinician consultation does not guarantee authorization or access to the requested blend.
What It Does in the Body
CJC-type GHRH activity and ipamorelin’s secretagogue activity are proposed to influence growth-hormone signaling through different pathways. The theoretical pairing does not demonstrate synergy or safety. Reliable onset, peak clinical benefit, and duration for the informal wellness combination remain unknown, especially when DAC identity is unclear.
Benefits & Reported Experiences
Hormone-marker changes should not be equated with stronger muscle, better sleep, healed injuries, or longer life. Those outcomes require studies of the exact combination and relevant population. A community explanation can make the theory understandable while still leaving these clinical endpoints unanswered.
Side Effects & Risks
Individual-agent safety information cannot fully characterize an unstudied blend. Growth-hormone and IGF-related effects require clinical context, and adverse-event detection depends on actual exposure and follow-up. A claim of selectivity does not establish that the combination is safe for everyone or that long-term effects are known.
Delivery Options
The route in a community injection chart differs from some published clinical research. That mismatch should remain visible rather than be resolved through an assumed conversion. This profile provides no administration technique, reconstitution, or schedule around meals, sleep, or exercise.
Product Quality & Storage
Confirm DAC status, constituent proportions, salt or formulation, and whether there is any lawful clinical product. A generic CJC label is insufficient. Do not guess storage for an unapproved blend; exact authorized-product instructions would be required if a legal patient-care route were established.
Combinations & Interactions
No additional performance stack is presented. Pairing two secretagogues does not justify adding testosterone, other GHRPs, or post-cycle drugs. A clinical review should consider the complete exposure history and the goal before accepting the premise that several hormone pathways need simultaneous manipulation.
Talking With Your Provider
Discuss fatigue, poor recovery, or suspected endocrine issues as symptoms with a clinician. Ask whether testing supports a specific diagnosis and which established options fit it. Interest in this pairing can support an informed evidence conversation without promising a prescription or treating a community protocol as a medical plan.
Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.
Compounding is appropriate only when lawful for the specific substance and patient; some substances may be unavailable. Finished FDA-approved medicines may also be dispensed by licensed non-compounding pharmacies.
Questions about what you read?
Explore the research library Create a free account
Educational information only. A free account lets you request review of your care goals. This profile does not establish availability, clinical suitability or access to the named compound.
Explore clinically appropriate options with a licensed provider. Inquiry does not guarantee a prescription, research-program acceptance or access to a particular substance.
Questions worth bringing to your appointment.
- Are there alternatives that address my goal?
- If treatment is appropriate, what monitoring and follow-up would I need?
- Could my health history or current medicines change the risks?
Saved discussion topics 0
Save topics you would like to discuss with your healthcare provider. Saving is an expression of interest, not a treatment request or medical recommendation.
Saved only in this browser, on this device—not in a patient account. Other people using this browser may see your list. Clear it when using a shared device. This list is not sent to our team.
Explore your next step with SEINE BIO.
Bring your questions to a wellness consultation. Inclusion in this library does not indicate prescribing or product availability. A consultation does not guarantee a prescription.
Explore consultations Back to Blend names: GLOW & KLOWEducational information · U.S. context · October 7, 2026. No ordering, personalized dosing or injection instructions.
Bring your saved topics to your care team.
Members can select up to five favorites and send a message for review. Your saved list stays in this browser until you choose what to submit.
Choose saved topics for review →